<unk> , sold under the brand name Paxlovid, is a co-packaged medication used as a treatment for COVID-19. It contains the antiviral medications<unk>  and ritonavir. It is taken by mouth. In December 2021, the co-packaged medication was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID-19. The co-packaged medication is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. The co-packaged medication was approved for medical use in the United Kingdom in December 2021, and in the European Union in January 2022. Health Canada approved Paxlovid through emergency use authorization on January 18th,2022
Nirmatrelvir/ritonavir
Atazanavir/ritonavir
Atazanavir/cobicistat
Darunavir/cobicistat
Cabotegravir/rilpivirine
Ombitasvir/paritaprevir/ritonavir
Abacavir/lamivudine
Dolutegravir/rilpivirine